Zevalin In-111 and Hematological toxicity
Result of checking the interaction of drug Zevalin In-111 and disease Hematological toxicity for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:The radiation dose resulting from therapeutic exposure to Y-90 radiolabeled ibritumomab tiuxetan may result in secondary malignancies. Myelodysplastic syndrome (MDS) and/or acute myelogenous leukemia (AML) has been reported in clinical trials with ibritumomab tiuxetan. It is recommended to monitor patients for hematological toxicity including development of MDS or AML.
Generic Name: ibritumomab
Brand Name: Y-90 Zevalin, In-111 Zevalin
Synonyms: Zevalin In-111 (Intravenous)
Zevalin In-111 - toksyczność hematologiczna 
Zevalin In-111 - toxicidade hematológica 
Zevalin In-111 - ketoksikan hematologi 
Zevalin In-111 - toksisitas hematologis 
Zevalin In-111 - tossicità ematologica 
Zevalin In-111 - toxicité hématologique 
Zevalin In-111 - hämatologische Toxizität 
Zevalin In-111 - toxicidad hematológica 
Zevalin In-111 - гематологическая токсичность 
Zevalin In-111 - hematolojik toksisite 
Zevalin In-111 - سمية دموية 
Zevalin In-111 - 血液学毒性